2023 World Conference on Lung Cancer (Posters)-EP08.03. S-1 and CDDP with Concurrent TRT Followed by Durvalumab in Elderly Population with Unresectable, LA-NSCLC in Japan: Post-hoc Analysis of SAMURAI

EP08.03. S-1 and CDDP with Concurrent TRT Followed by Durvalumab in Elderly Population with Unresectable, LA-NSCLC in Japan: Post-hoc Analysis of SAMURAI - PDF(Slides)

Back to course

Pdf Summary

A post-hoc analysis of the SAMURAI study in Japan examined the use of S-1 and CDDP with concurrent thoracic radiotherapy (TRT), followed by durvalumab in elderly patients with unresectable, locally advanced non-small cell lung cancer (LA-NSCLC). The study aimed to evaluate the efficacy and safety of this treatment approach in this patient population. The primary endpoint of the study, the 1-year progression-free survival (PFS) rate, was achieved with a rate of 72.5%. The study also analyzed the survival impact in the elderly population and found that outcomes with this treatment approach were comparable to those in patients younger than 70 years. Adverse events were reported in both the concurrent TRT phase and the consolidation phase, with neutropenia, anorexia, and esophagitis being the most common events. The study concluded that S-1 and CDDP with concurrent TRT followed by durvalumab could be a viable treatment option for the elderly population with unresectable LA-NSCLC. Further follow-up is needed to assess long-term outcomes. The study was supported by AstraZeneca and conducted at multiple centers in Japan.

Asset Subtitle

Shigeru Tanzawa

Meta Tag

Speaker Shigeru Tanzawa

Topic Local-Regional NSCLC: Novel Therapies & Trials

Keywords

post-hoc analysis

SAMURAI study

S-1

CDDP

thoracic radiotherapy

elderly patients

unresectable

NSCLC

efficacy

safety